Therapeutic strategy for ALK/ROS driven NSCLC
Jan Van Meerbeeck (Belgium)
Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine
Number: 10
Disease area: Thoracic oncology
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Jan Van Meerbeeck (Belgium). Therapeutic strategy for ALK/ROS driven NSCLC. New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you: